CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection

Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients

Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen

This approval authorizes the company to export Ibuprofen to the Chinese markets

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA

DOVBLERON marks the 13th addition to Innovent’s commercial portfolio

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy

Jiangsu Hengrui Pharmaceuticals gets NMPA approval of oteseconazole Ccapsules

Oteseconazole Capsules were found to be safe and more effective than fluconazole

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape